Excision repair cross complementing-1 gene expression in small cell lung cancer and chemo-sensitivity to cisplatin/etoposide regimen

目的 观察小细胞肺癌标本中切除修复交叉互补基因1(ERCC1)表达的特点及其对顺铂联合化疗效果的影响.方法 对60例初治小细胞肺癌患者的气管镜活检标本,用免疫组织化学方法检测ERCC1蛋白,同时分析ERCC1蛋白水平与顺铂/依托泊苷化疗疗效关系、患者中位生存期的关系.结果 ERCC1在小细胞肺癌标本中表达率为23.3%,与病程和患者年龄无明显相关.ERCC1表达阳性患者顺铂/依托泊苷一线化疗有效率为42.9%,显著低于ERCC1(-)患者的73.1%.结论 ERCC1在部分小细胞肺癌标本存在表达,ERCC1阳性的小细胞肺癌对顺铂的化疗敏感性降低.Objective To evaluate the expression pattern of excision repair cross comlementing-1 ( ERCC1 ) gene and its relation with ciaplatin-based chemotherapy. Methods Sixty small-cell lung cancer samples were studied for ERCC1 expression by immunohistochemistry. The association of ERCC1 gene ex-pression to response of ciaplatin/etoposide chemotherapy and patients' survival was analyzed. Results ERCC1 expression detected by imlnunohistochemistry was 23.3% in small-cell lung cancer samples and not related to stage or age of patients. Response rate in ERCC1 positive patients to ciaplatin/etoposide chemotherapy was 42.3% ,which was significantly lower than that in ERCC1 ( - ) patients of 73. 1%. Statistical significance was not reached for ERCC1 expression and median survival analysis. Conclusion ERCC1 expression in small-cell lung cancer samples could serve as a predictive marker for first-line ciapl-atin/etoposide chemotherapy.中文核心期刊要目总览(PKU)中国科技核心期刊(ISTIC)中国科学引文数据库(CSCD)02222-2232